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Background
Reports show that 1.8–8.4% of male patients receiving
efavirenz (EFV) develop gynecomastia by unclear multi-
ple mechanisms, one of them being a direct binding to
estrogen receptors. However, EFV can independently
cause gynecomastia by increasing prolactin levels and
we postulate that this mechanism is a dopamine-
mediated one. Dopamine is a strong prolactin inhibitor.
Conversely, a lack of dopamine can cause hyperprolacti-
nemia. On the other hand, dopamine is an antidepres-
sant neurotransmitter and depression is one of the very
frequent adverse reactions to EFV. We present the case
of an HIV-positive newly diagnosed male patient who
developed mild depression and amplified a preexistent
gynecomastia after the introduction of an EFV-contain-
ing antiretroviral regimen.
Case report
A 41-year-old male patient, diagnosed with CDC-A2
HIV infection, had been receiving antiretroviral treat-
ment (ART) for 14 months with ABC+3TC+EFV and
had been favorably evaluated regarding the immuno-vir-
ological course. Nevertheless, after 6 months of ART he
developed bilateral gynecomastia with mastodynia and
he reported also mild depression. A careful anamnesis
discovered a previous mild gynecomastia with also mild
rising in prolactin level. Current clinical examination
showed moderate bilateral concentric gynecomastia. The
breast echography was normal. Brain MRI was per-
formed and can’t exclude microprolactinoma. Lab find-
ings showed normal levels of estrogen and testosterone
and high levels of prolactin. We considered dropping
EVF and replacing it with raltegravir. After switching
(raltegravir doesn’t affect the endocrine ax) mastodynia
ceased in one month, the breast volume regressed in
2-3 months and the prolactin level decreased. Besides,
the depression’s symptoms diminished.
Conclusion
In the presented case, gynecomastia was related to hyper-
prolactinemia and the last was related to EFV use. More-
over, the patient presented also an EFV related depression.
It makes sense to consider a unique mechanism for both
EFV’s adverse reactions: a drop in dopamine-level caused
by EFV, which produce depression and also a hyperprolac-
tinemia with gynecomastia.
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